Article
Successful treatment of Afatinib plus Apatinib using for a lung adenocarcinoma patient with HER-2 V659D mutation: a rare case report.
Anti-cancer drugs - 1 Apr 2021
Sun Chao, Xu Yinghui, Wang Xu, Guo Ye, Qiu Shi, Shao Guoguang, Yang Zhiguang, Liu Yunpeng, Zhang Peng, Ma Kewei
Abstract excerpt
Lung cancer is one of the most important and lethal cancers in the world. Human epidermal growth factor 2 (HER2) is a member of the erbB receptor tyrosine kinase family. The incidence of HER2 kinase domain mutations in adenocarcinoma of lung ranges from 1% to 3%. HER2 V659D mutation is located in the trans-membrane domain (TMD) with only a few cases reported before, and importantly, there were no more standard...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.